IE
CRVS icon

Israel Englander’s Corvus Pharmaceuticals CRVS Stock Holding History

Israel Englander’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-121,200
Closed -$385K – 5924
2025
Q1 		$385K Sell
121,200
-60,000
-33% -$283K ﹤0.01% 4961
2024
Q4 		$969K Buy
181,200
+28,400
+19% +$212K ﹤0.01% 4223
2024
Q3 		$807K Buy
+152,800
New +$549K ﹤0.01% 4439
2021
Q4 		– Sell
-103,100
Closed -$499K – 6881
2021
Q3 		$499K Buy
+103,100
New +$305K ﹤0.01% 5349

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Israel Englander's CRVS Position: Q2 2026 in Review

Israel Englander increased its Corvus Pharmaceuticals (CRVS) stake by 21% in Q2 2026, buying an estimated $2.52M and bringing the position to 1,047,985 shares worth $15.7M. The position accounts for 0.01% of the portfolio, ranked #1856.

Israel Englander first reported a position in CRVS in Q1 2016 and has held it in 37 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Israel Englander held 1,047,985 shares of Corvus Pharmaceuticals worth $15.7M as of Q2 2026.
  • Israel Englander bought 181,623 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.52M.
  • Corvus Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1856 holding.
  • Israel Englander first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 37 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.